检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.

Hanae Ida,Toshio Shimizu,Makoto Nishino,Yoshiaki Nakamura,Shu Yazaki,Yuki Katsuya,Jun Sato,Takafumi Koyama,Satoru Iwasa,Kazuki Sudo,Shunsuke Kondo,Kan Yonemori,Kohei Shitara,Satoshi Shiono,Daiko Matsuoka, Keisuke Yasuda,Yohei Otake,Takuya Suzuki,Takao Takase,Shuya Takashima,Kohei Yamaguchi,Taro Semba,Noboru Yamamoto

Cancer research communications（2023）

引用 0|浏览24
暂无评分
摘要
This phase Ib part of a phase Ib/II study assessed the tolerability and activity of a liposomal formulation of eribulin (E7389-LF) plus nivolumab in 25 patients with advanced solid tumors. The combination was tolerable overall; 4 patients had a partial response. Vasculature and immune-related biomarker levels increased, suggesting vascular remodeling.
更多
查看译文
关键词
liposomal formulation,eribulin,advanced solid tumors,phase ib/ii,nivolumab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要